First Light Asset Management LLC Trims Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

First Light Asset Management LLC decreased its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 16.0% during the first quarter, HoldingsChannel reports. The firm owned 4,874,124 shares of the company’s stock after selling 931,060 shares during the period. Centessa Pharmaceuticals makes up approximately 7.9% of First Light Asset Management LLC’s holdings, making the stock its 3rd biggest holding. First Light Asset Management LLC’s holdings in Centessa Pharmaceuticals were worth $70,090,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. Trexquant Investment LP boosted its stake in Centessa Pharmaceuticals by 1.1% in the first quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock worth $3,796,000 after buying an additional 2,810 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after buying an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. bought a new position in Centessa Pharmaceuticals during the first quarter valued at approximately $47,000. Finally, Barclays PLC raised its stake in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CNTA. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Wall Street Zen cut Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a “buy” rating and a $35.00 target price for the company. Truist Financial started coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 target price for the company. Finally, Oppenheimer began coverage on Centessa Pharmaceuticals in a research note on Friday. They issued an “outperform” rating and a $40.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.50.

Centessa Pharmaceuticals Trading Up 1.4%

Shares of CNTA opened at $16.79 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average price is $15.77 and its 200-day moving average price is $14.44. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -9.38 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the sale, the insider directly owned 216,485 shares in the company, valued at $3,030,790. The trade was a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 12,000 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.02, for a total value of $168,240.00. Following the completion of the transaction, the general counsel owned 105,386 shares of the company’s stock, valued at approximately $1,477,511.72. This trade represents a 10.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 171,322 shares of company stock worth $2,472,814. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.